Compare Stocks: CMPX, AVBP, RARE, and ABSI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABSI Absci	$9.65 +4.1%	$8.71	$2.24 ▼ $12.06	$1.66B	2.42	2.89 million shs	7.73 million shs
AVBP ArriVent BioPharma	$28.90 +1.9%	$30.30	$17.00 ▼ $35.83	$1.43B	1.35	439,347 shs	1.24 million shs
CMPX Compass Therapeutics	$1.90 +2.7%	$2.17	$1.61 ▼ $6.88	$342.17M	0.95	2.29 million shs	8.19 million shs
RARE Ultragenyx Pharmaceutical	$14.51 +0.1%	$23.88	$12.73 ▼ $39.89	$1.43B	0.31	5.41 million shs	13.33 million shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABSI Absci	0.00%	+17.54%	+3.99%	+30.23%	+278.43%
AVBP ArriVent BioPharma	0.00%	-0.34%	-0.96%	-8.95%	+65.05%
CMPX Compass Therapeutics	0.00%	-5.00%	-19.49%	-5.94%	-45.87%
RARE Ultragenyx Pharmaceutical	0.00%	+1.47%	-42.69%	-47.12%	-49.46%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABSI Absci	$9.65 +4.1%	$8.71	$2.24 ▼ $12.06	$1.66B	2.42	2.89 million shs	7.73 million shs
AVBP ArriVent BioPharma	$28.90 +1.9%	$30.30	$17.00 ▼ $35.83	$1.43B	1.35	439,347 shs	1.24 million shs
CMPX Compass Therapeutics	$1.90 +2.7%	$2.17	$1.61 ▼ $6.88	$342.17M	0.95	2.29 million shs	8.19 million shs
RARE Ultragenyx Pharmaceutical	$14.51 +0.1%	$23.88	$12.73 ▼ $39.89	$1.43B	0.31	5.41 million shs	13.33 million shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABSI Absci	0.00%	+17.54%	+3.99%	+30.23%	+278.43%
AVBP ArriVent BioPharma	0.00%	-0.34%	-0.96%	-8.95%	+65.05%
CMPX Compass Therapeutics	0.00%	-5.00%	-19.49%	-5.94%	-45.87%
RARE Ultragenyx Pharmaceutical	0.00%	+1.47%	-42.69%	-47.12%	-49.46%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABSI Absci	2.80	Moderate Buy	$13.71	42.12% Upside
AVBP ArriVent BioPharma	2.70	Moderate Buy	$44.86	55.22% Upside
CMPX Compass Therapeutics	2.88	Moderate Buy	$11.77	519.43% Upside
RARE Ultragenyx Pharmaceutical	2.48	Hold	$34.42	137.22% Upside

Current Analyst Ratings Breakdown

Latest CMPX, AVBP, RARE, and ABSI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/18/2026	RARE Ultragenyx Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$18.00 ➝ $20.00
9/18/2026	RARE Ultragenyx Pharmaceutical	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$31.00 ➝ $32.00
9/18/2026	RARE Ultragenyx Pharmaceutical	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$37.00 ➝ $39.00
9/18/2026	RARE Ultragenyx Pharmaceutical	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$33.00 ➝ $39.00
9/9/2026	ABSI Absci	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
9/8/2026	ABSI Absci	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$15.00
9/8/2026	ABSI Absci	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$13.00 ➝ $16.00
9/4/2026	RARE Ultragenyx Pharmaceutical	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$28.00 ➝ $19.00
9/4/2026	RARE Ultragenyx Pharmaceutical	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$43.00 ➝ $32.00
9/3/2026	RARE Ultragenyx Pharmaceutical	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
9/3/2026	RARE Ultragenyx Pharmaceutical	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$77.00 ➝ $28.00

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABSI Absci	$2.80M	591.44	N/A	N/A	$1.26 per share	7.66
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	$7.44 per share	N/A
CMPX Compass Therapeutics	$850K	402.55	N/A	N/A	$1.11 per share	1.71
RARE Ultragenyx Pharmaceutical	$673M	2.13	N/A	N/A	($0.83) per share	-17.48

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABSI Absci	-$115.18M	-$0.80	N/A	N/A	N/A	-7,756.38%	-61.71%	-54.52%	11/16/2026 (Estimated)
AVBP ArriVent BioPharma	-$166.31M	-$3.62	N/A	N/A	N/A	N/A	-50.26%	-46.66%	11/16/2026 (Estimated)
CMPX Compass Therapeutics	-$66.49M	-$0.40	N/A	N/A	N/A	N/A	-38.71%	-34.72%	11/4/2026 (Estimated)
RARE Ultragenyx Pharmaceutical	-$575M	-$5.84	N/A	N/A	N/A	-81.79%	-1,024.42%	-44.40%	11/3/2026 (Estimated)

Latest CMPX, AVBP, RARE, and ABSI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	AVBP ArriVent BioPharma	-$0.9873	-$1.05	-$0.0627	-$1.05	N/A	N/A
8/11/2026	Q2 2026	ABSI Absci	-$0.1910	-$0.21	-$0.0190	-$0.21	$0.92 million	$0.32 million
8/6/2026	Q2 2026	CMPX Compass Therapeutics	-$0.1107	-$0.13	-$0.0193	-$0.13	($0.60) million	N/A
8/4/2026	Q2 2026	RARE Ultragenyx Pharmaceutical	-$1.22	-$0.90	+$0.32	-$0.90	$183.08 million	$214.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABSI Absci	N/A	N/A	N/A	N/A	N/A
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	N/A
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABSI Absci	N/A	10.63	10.63
AVBP ArriVent BioPharma	N/A	14.16	14.16
CMPX Compass Therapeutics	N/A	11.22	11.22
RARE Ultragenyx Pharmaceutical	N/A	1.73	1.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABSI Absci	52.05%
AVBP ArriVent BioPharma	9.48%
CMPX Compass Therapeutics	68.43%
RARE Ultragenyx Pharmaceutical	97.67%

Insider Ownership

Company	Insider Ownership
ABSI Absci	10.52%
AVBP ArriVent BioPharma	8.58%
CMPX Compass Therapeutics	18.70%
RARE Ultragenyx Pharmaceutical	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABSI Absci	140	171.61 million	153.56 million	Optionable
AVBP ArriVent BioPharma	77	49.31 million	45.08 million	N/A
CMPX Compass Therapeutics	39	180.09 million	146.41 million	Not Optionable
RARE Ultragenyx Pharmaceutical	1,371	98.59 million	93.46 million	Optionable

CMPX, AVBP, RARE, and ABSI Headlines

Recent News About These Companies

Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says

September 20 at 3:22 AM | americanbankingnews.com

Canaccord Genuity Group Forecasts Strong Price Appreciation for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock

September 20 at 3:22 AM | americanbankingnews.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Expected to Rise, Citigroup Analyst Says

September 20 at 2:40 AM | americanbankingnews.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Sees Strong Trading Volume Following Analyst Upgrade

September 20 at 1:21 AM | americanbankingnews.com

Leerink Partners Keeps Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

September 19 at 10:39 PM | theglobeandmail.com

Ultragenyx Pharmaceutical (RARE) Receives a Buy from Canaccord Genuity

September 19 at 10:39 PM | theglobeandmail.com

How Investors Are Reacting To Ultragenyx Pharmaceutical (RARE) First-In-Disease Gene Therapy Approval For FAYUVI

September 19 at 10:39 PM | finance.yahoo.com

Andelyn and Its Curator® Platform Achieve First FDA-Approved Commercial Gene Therapy Manufacturing Milestone Following FDA Approval of Ultragenyx's FAYUVI™ to Treat ...

September 18 at 8:13 PM | newswise.comN

Ultragenyx Gene Therapy Is First Approved Treatment for Rare Neuro Disease Sanfilippo

September 18 at 8:13 PM | medcitynews.comM

Ultragenyx sets $3.95m list price for fatal rare disease therapy

September 18 at 3:12 PM | emjreviews.comE

Ultragenyx Pharmaceutical stock jumps on Fayuvi FDA approval and fresh Cantor Fitzgerald target

September 18 at 3:12 PM | ad-hoc-news.deA

Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Expected to Rise, Morgan Stanley Analyst Says

September 18 at 12:35 PM | marketbeat.com

RARE Stock Up 13% on FDA Approval of Sanfilippo Syndrome Gene Therapy

September 18 at 11:50 AM | zacks.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Sees Large Volume Increase After Analyst Upgrade

September 18 at 10:39 AM | marketbeat.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Raised to $32.00

September 18 at 10:35 AM | marketbeat.com

Ultragenyx Wins FDA Approval For FAYUVI In Pediatric MPS IIIA

September 18 at 10:11 AM | rttnews.com

Ultragenyx wins first-ever FDA approval in Sanfilippo syndrome type A

September 18 at 10:11 AM | thepharmaletter.comT

Canaccord Genuity Group Increases Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $39.00

September 18 at 8:41 AM | marketbeat.com

Ultragenyx (RARE) Surges 12.6%: Is This an Indication of Further Gains?

September 18 at 8:30 AM | zacks.com

Cantor Fitzgerald Forecasts Strong Price Appreciation for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock

September 18 at 8:05 AM | marketbeat.com

Ultragenyx Pharmaceutical Inc. (RARE) Discusses FDA Approval of FAYUVI as First Treatment for Sanfilippo Syndrome Type A Transcript

September 18 at 3:00 AM | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CMPX, AVBP, RARE, and ABSI Company Descriptions

Absci NASDAQ:ABSI

$9.65 +0.38 (+4.10%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$9.59 -0.06 (-0.63%)

As of 09/18/2026 07:59 PM Eastern

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.

ArriVent BioPharma NASDAQ:AVBP

$28.90 +0.54 (+1.90%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$28.94 +0.05 (+0.16%)

As of 09/18/2026 07:30 PM Eastern

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Compass Therapeutics NASDAQ:CMPX

$1.90 +0.05 (+2.70%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.89 -0.01 (-0.58%)

As of 09/18/2026 07:56 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Ultragenyx Pharmaceutical NASDAQ:RARE

$14.51 +0.01 (+0.07%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$14.55 +0.04 (+0.25%)

As of 09/18/2026 07:59 PM Eastern

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CMPX, AVBP, RARE, and ABSI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CMPX, AVBP, RARE, and ABSI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CMPX, AVBP, RARE, and ABSI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CMPX, AVBP, RARE, and ABSI Company Descriptions

Absci NASDAQ:ABSI

ArriVent BioPharma NASDAQ:AVBP

Compass Therapeutics NASDAQ:CMPX

Ultragenyx Pharmaceutical NASDAQ:RARE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CMPX, AVBP, RARE, and ABSI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CMPX, AVBP, RARE, and ABSI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CMPX, AVBP, RARE, and ABSI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CMPX, AVBP, RARE, and ABSI Company Descriptions

Absci NASDAQ:ABSI

ArriVent BioPharma NASDAQ:AVBP

Compass Therapeutics NASDAQ:CMPX

Ultragenyx Pharmaceutical NASDAQ:RARE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools